Allogene Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Allogene Therapeutics, Inc. (ALLO) had Debt Securities, Available-for-sale, Unrealized Loss Position of $0 as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-12
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $0.00.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $0.00.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $0.00.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $2.50M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-12 |
| 2025-09-30 | $2.50M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 |
| 2024-06-30 | $17.70M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $29.40M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $48.40M 10-K · filed 2025-03-13 |
| 2023-09-30 | $81.00M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $191.80M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $279.60M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $329.40M 10-K/A · filed 2024-03-14 |
| 2022-09-30 | $153.70M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $16.90M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 |
| 2021-12-31 | $0.00 10-K/A · filed 2024-03-14 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-04 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-05 |
| 2020-12-31 | $5.00M 10-K · filed 2022-02-23 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |